3
Ridec

Ridec

N° 2 Volumen 15

Invasive Meningococcal Disease in Spain: from epidemiology to vaccination strategies

Section: Artículo Especial

How to quote

Ayala Velasco R, García Pérez A, Montoro Montero I, Cisneros Leralta E, González Quero N, Salamanca Postigo E. Enfermedad meningocócica invasiva en España: de la epidemiología a las estrategias de vacunación. RIdEC 2022; 15(2):49-61.

Authors

1 Raúl Ayala Velasco, 2 Alejandro García Pérez, 3 Irene Montoro Montero, 3 Elisa Cisneros Leralta, 3 Natalia González Quero, 3 Elisa Salamanca Postigo

Position

1 Enfermero. Centro Salud el Sardinero. Santander, Cantabria (España).2 Enfermero. Centro Salud La Mejostilla. Cáceres (España). 3 Departamento Médico, GSK, Tres Cantos. Madrid (España).

Contact email: raul30373@hotmail.com

Abstract

Objective: to offer nursing professionals the most recent scientific evidence about Invasive Meningococcal Disease (IMD), in order to give an answer to their challenges as first line communicators regarding health and immunization in the community.  
Methods: a non-systemic review, bibliographic search in PubMed on epidemiology, clinical presentation, risk factors for IMD and vaccination against meningococcus, with narrative analysis. Epidemiological data on IMD in Spain / Europe was examined, as well as recommendations for vaccination in Spain.  
Results: in Spain and Europe, meningococcal serogroup B (MenB) causes the majority of IMD cases, and it affects mainly infants (< 1-year-old) and 1-to-4-year-old children. For many years, MenC has been the second most frequent serogroup in Spain; however, the number of MenC cases has been reduced due to vaccination. Currently, MenB is still the prevailing serogroup, followed by MenW and MenY. Developing an effective vaccine against MenB has represented a challenge, but recent scientific advances have led to the creation of two effective vaccines against MenB. Only one of them has the indication for infants and small children.   
Conclusions: this review provides updated information on IMD and antimeningococcal vaccination to nursing professionals, which can be helpful for their task of informing parents and patients. Besides, it complements their knowledge on administration and management of these vaccines in daily practice, in order to offer good-quality care which is effective and efficient.

Keywords:

meningococcal infection; invasive meningococcal disease; Neisseria meningitidis; serogroup; antimeningococcal vaccine; pandemics

Versión en Español

Título:

ENFERMEDAD MENINGOCÓCICA INVASIVA EN ESPAÑA: DE LA EPIDEMIOLOGÍA A LAS ESTRATEGIAS DE VACUNACIÓN

Artículo completo no disponible en este idioma / Full article is not available in this language

Bibliography

  1. GBD 2016 Meningitis Collaborators. Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018; 17(12):1061-82. Doi: http://doi.org/10.1016/S1474-4422(18)30387-9
  2. Centers for Disease Control and Prevention (CDCP). Meningitis. CDCP [internet] 2022 [citado 18 oct 2022]. Disponible en: https://www.cdc.gov/me-ningitis/index.html.
  3. World Health Organization (WHO). Meningitis. Key facts [internet] 2021 [citado 18 oct 2022]. Disponible en: https://www.who.int/news-room/fact-sheets/detail/meningitis.
  4. Oordt-Speets AM, Bolijn R, van Hoorn RC, Bhavsar A, Kyaw MH. Global etiology of bacterial meningitis: A systematic review and meta-analysis. PLoS One. 2018; 13(6):e0198772. Doi: http://doi.org/10.1371/journal.pone.0198772.
  5. Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century-an update for the clinician. Curr Neurol Neurosci Rep. 2015; 15(3):2. Doi: http://doi.org/10.1007/s11910-015-0524-6.
  6. Instituto de Salud Carlos III. Enfermedad meningocócica. Vigilancia de la temporada 2017-2018. Resultados de la Red Nacional de Vigilancia Epidemiológica. Ministerio de Ciencia, Innovación y Universidades [internet] 2019 [citado 18 oct 2022]. Disponible en: https://www.isciii.es/Que-Hacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/archivos%20A-Z/Enfer_Meningoc%C3%B3cica/RE-NAVE_EMI-2017-18.pdf.
  7. Instituto de Salud Carlos III. Informe Semanal de Vigilancia epidemiológica N°42 del año 2020. Boletín Epidemiológico Semanal en RED. Boletín nº 42, semana 40 [internet] 2020 [citado 18 oct 2022]. Disponible en: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSalud-PublicaRENAVE/EnfermedadesTransmisibles/Boletines/Documents/Boletin_Epidemiologico_en_red/boletines%20en%20red%202020/IS_N%C2%B A42-201013-WEB.pdf
  8. Instituto de Salud Carlos III. Informe Semanal de Vigilancia Epidemiológica en España N°44 del año 2021. Boletín Epidemiológico Semanal en RED [internet] 2021 [citado 18 oct 2022]. Disponible en: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/En-fermedadesTransmisibles/Boletines/Documents/Boletin_Epidemiologico_en_red/boletines%20en%20red%202021/IS_N%C2%BA44-211102_WEB.pdf.
    European Centre for Disease Prevention and Control (ECDP). Surveillance Atlas of Infectious
  9. Diseases. ECDP [internet] 2020 [citado 18 oct 2022]. Disponible en: https://atlas.ecdc.europa.eu/public/index.aspx?Dataset=27&HealthTopic=36.
  10. Caugant DA, Brynildsrud OB. Neisseria meningitidis: using genomics to understand diversity, evolution and pathogenesis. Nat Rev Microbiol. 2020; 18(2):84-96. Doi: http://doi.org/10.1038/s41579-019-0282-6
  11. Read RC. Neisseria meningitidis; clones, carriage, and disease. Clin Microbiol Infect. 2014; 20(5):391-5. Doi: http://doi.org/10.1111/1469-0691.12647
  12. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010; 10(12):853-61. Doi: http://doi.org/10.1016/S1473-3099(10)70251-6
  13. Caugant DA, Høiby EA, Magnus P, Scheel O, Hoel T, Bjune G, et al. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol. 1994; 32(2):323-30. Doi: http://doi.org/10.1128/JCM.32.2.323-330.1994
  14. Pathan N, Faust SN, Levin M. Pathophysiology of meningococcal meningitis and septicaemia. Arch Dis Child. 2003; 88(7):601-7. Doi: http://doi.org/10.1136/adc.88.7.601
  15. Grupo de trabajo vacunación frente a EMI de la Ponencia de Programa y Registro de Vacunaciones. Recomendaciones de vacunación frente a enfermedad meningocócica invasiva. Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad, Consumo y Bienestar Social, Marzo 2019 [internet] 2019 [citado 18 oct 2022]. Disponible en: https://www.mscbs.gob.es/profesionales/sa-ludPublica/prevPromocion/vacunaciones/docs/Recomendaciones_Vacunacion_Meningococo.pdf.
  16. Dretler AW, Rouphael NG, Stephens DS. Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development. Hum Vaccin Immunother. 2018; 14(5):1146-60. Doi: http://doi.org/10.1080/ 21645515.2018.1451810
  17. GAVI. At least 80 million children at risk of disease as COVID-19 disrupts vaccination efforts, warn Gavi, WHO and UNICEF [internet] 2020 [citado 18 oct 2022]. Disponible en: https://www.gavi.org/news/media-room/least-80-million-children-risk-disease-covid-19-disrupts-vac-cination-efforts.
  18. World Health Organization (WHO). Maintaining essential health services: operational guidance for the COVID-19 context interim guidance [internet]. Geneva: WHO; 2020 [citado 18 oct 2022]. Disponible en: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-essential_health_services-2020.2.
  19. Boulton J. Meningitis immunisation: challenges, successes and new developments. Br J Nurs. 2013; 22(1):20-5. Doi: http://doi.org/10.12968/bjon.2013.22.1.20
  20. Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012; 11(9):774-83. Doi: http://doi.org/10.1016/S1474-4422(12)70180-1
  21. Principi N, Esposito S. Bacterial meningitis: new treatment options to reduce the risk of brain damage. Expert Opin Pharmacother. 2020; 21(1):97-105. Doi: http://doi.org/10.1080/14656566.2019.1685497
  22. Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012; 30 Suppl 2:B3-9. Doi: http://doi.org/10.1016/j.vaccine.2011.12.062
  23. Manual de vacunas en línea de la AEP. 30. Meningococos. Comité Asesor de Vacunas [internet] 2022 [citado 18 oct 2022]. Disponible en: https://vacunasaep.org/documentos/manual/cap-30.
  24. Álvarez García FJ, Cilleruelo Ortega MJ, Álvarez Aldeán J, Garcés-Sánchez M, Garrote Llanos E, Iofrío de Arce A, et al. Immunization schedule of the Pediatric Spanish Association: 2022 recommendations. An Pediatr (Engl Ed). 2022; 96(1):59.e1-59.e10. Doi: http://doi.org/10.1016/anpede.2021.11.002
  25. Ministerio de Sanidad, Consumo y Bienestar Social. Vacunas y Programa de Vacunación. Calendario de vacunación a lo largo de toda la vida 2022 [internet] 2022 [citado 18 oct 2022] Disponible en: https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/ca-lendario-y-coberturas/docs/CalendarioVacunacion_Todalavida.pdf
  26. Sohn WY, Tahrat H, Novy P, Bekkat-Berkani R. Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical practices. Expert Rev Vaccines. 2022; 21(3):325-35. Doi: http://doi.org/10.1080/14760584.2022.2021881
  27. Packnett E, Irwin DE, Novy P, Watson PS, Whelan J, Moore-Schiltz L, et al. Meningococcal-group B (MenB) vaccine series completion and adherence to dosing schedule in the United States: A retrospective analysis by vaccine and payer type. Vaccine. 2019; 37(39):5899-908. Doi: http://doi.org/10.1016/j.vaccine.2019.06.065
  28. Bryan P, Seabroke S, Wong J, Donegan K, Webb E, Goldsmith C, et al. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study. Lancet Child Adolesc Health. 2018; 2(6):395-403. Doi: http://doi.org/10.1016/S2352-4642(18)30103-2
  29. Prymula R, Esposito S, Zuccotti GV, Xie F, Toneatto D, Kohl I, et al. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I). Hum Vaccin Immunother. 2014; 10(7):1993-2004. Doi: http://doi.org/10.4161/hv.28666
  30. De Serres G, Billard MN, Gariépy MC, Rouleau I, Toth E, Landry M, et al. Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada. Vaccine. 2018; 36(52):8039-46. Doi: http://doi.org/10.1016/j.vaccine.2018.10.095
  31. Abad R, Martinón-Torres F, Santolaya ME, Banzhoff A, González-Inchausti C, Graña MG, et al. From a pathogen's genome to an effective vaccine: the four-component meningococcal serogroup B vaccine. Rev Esp Quimioter. 2019; 32(3):208-16.
  32. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine. 2001; 19(17-19):2688-91. Doi: http://doi.org/10.1016/s0264-410x(00)00554-5
  33. Martinón-Torres F, Banzhoff A, Azzari C, de Wals P, Marlowe R. Marshall H, et al. Recent advances in the prevention of meningococcal B disease: real evidence from 4CMenB vaccination. Vacunas. 2021; 22(3):189-202. Doi: http://doi.org/10.1016/j.vacun.2021.07.002